Catalog No.
Product Name
Application
Product Information
Citations
-
Cell-cycle Inhibitor, Senescence Inducer, Apoptosis Inducer, Antiproliferative Agent
Anticancer agent 299 is a cell-cycle inhibitor that functions as a senescence and apoptosis inducer, exhibiting significant antiproliferative effects on cancer cells. This compound demonstrates selective cytotoxicity against cancerous cells with minimal impact on non-tumoral chondrocyte cells at therapeutic concentrations. Anticancer agent 299 is particularly useful for research related to ER+/HER2− breast cancer and BRAF-mutant melanoma. -
Apoptosis Inducer
Glucobrassicin is an indole-based compound that acts as an apoptosis inducer by disrupting microtubule integrity in both plant and mammalian cells. Its primary biological activity includes the induction of programmed cell death in mammalian cancer cells, making it a valuable tool in cancer research. Additionally, Glucobrassicin demonstrates significant effects on plant growth, as it inhibits seed germination and root growth at elevated concentrations. This dual functionality makes Glucobrassicin relevant for studies in both oncology and plant biology. -
Nucleoside Metabolite
(R)-b-Aminoisobutyric acid is a nucleoside metabolite that serves as an effective amino donor. It plays a significant role in various biochemical pathways, making it valuable for studies on amino acid metabolism and nucleoside synthesis. This compound can be used in research applications focused on metabolic disorders and the regulation of nucleoside levels within cells. -
Anticancer Agent
BMY-25551 is a potent Mitomycin A analogue, exhibiting 8 to 20 times greater cytotoxicity compared to Mitomycin C in murine and human tumor cell lines. This compound is primarily investigated as an anticancer agent and shows potential in research related to cancer therapies and hematologic suppression. Its enhanced efficacy makes BMY-25551 a valuable tool for exploring mechanisms of tumor cell inhibition. -
MIF Inhibitor
MIF-IN-1 is a potent inhibitor of macrophage migration inhibitory factor (MIF), with a reported pIC50 of 6.87. This compound is designed to selectively inhibit MIF activity, which plays a critical role in various inflammatory and immune responses. MIF-IN-1 is suitable for research applications focused on inflammation, autoimmune diseases, and cancer biology, providing valuable insights into MIF-mediated pathways. -
D-DT Inhibitor
RGB097 is a potent inhibitor of D-dopachrome tautomerase (D-DT), demonstrating an IC50 value of 0.5 µM. This compound exhibits significant biological activity and has potential applications in cancer research, particularly in elucidating the role of D-DT in oncogenesis and tumor progression. -
MIF Inhibitor
MIF-IN-5 is a potent and reversible inhibitor of macrophage migration inhibitory factor (MIF), exhibiting a competitive mechanism of action. With an IC50 of 4.8 μM and a Ki value of 3.3 μM, it effectively disrupts MIF's biological activity. This compound is valuable for research applications involving inflammation, immune response modulation, and potential therapeutic strategies targeting various diseases associated with MIF dysregulation. -
MIF Inhibitor
HTS05585 is a selective inhibitor of macrophage migration inhibitory factor (MIF), demonstrating a Kd value of 0.29 μM via microscale thermophoresis and 0.32±0.01 μM confirmed by isothermal titration calorimetry. This compound effectively inhibits the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, from LPS-stimulated macrophages. HTS05585 is a valuable tool for studying inflammation-related diseases, particularly in the context of sepsis research. -
MIF tautomerase Inhibitor
TE-11 is a potent MIF tautomerase inhibitor, exhibiting an IC50 value of 5.63 μM. This compound effectively ameliorates CD-like colitis and reduces migration of MIF-induced eosinophils and neutrophils. Additionally, TE-11 prevents M1 polarization and the associated metabolic reprogramming, making it a valuable tool for research in inflammatory and autoimmune disorders. -
Apoptosis Inducer
Moracin G is an apoptosis inducer that acts as a kinase modulator and receptor ligand. It forms stable interactions with key proteins, including AKT1, COX2, and Estrogen receptor 1, while competitively inhibiting specific kinase activity. By binding to MELK, Moracin G disrupts cell cycle regulation, leading to the impairment of cancer cell survival and proliferation, as well as the induction of apoptosis. This compound is relevant in research focusing on periodontitis and breast cancer. -
PERK Activator
MK-28 is a potent and selective activator of the protein kinase PERK (PKR-like ER kinase). This compound demonstrates significant pharmacokinetic properties, with a notable ability to penetrate the blood-brain barrier in murine models. MK-28 is primarily used in research related to ER stress response and unfolded protein response pathways, providing valuable insights into cellular homeostasis and neurodegenerative diseases. -
PERK Inhibitor
PERK-IN-2 is a highly potent inhibitor of the PERK (PKR-like ER kinase) pathway, exhibiting an IC50 of 0.2 nM. This compound effectively modulates unfolded protein response (UPR) signaling, making it valuable for studies investigating the roles of PERK in cellular stress responses and related diseases. Applications include research on cancer biology, neurodegeneration, and metabolic disorders. -
PERK Inhibitor
PERK-IN-4 is a highly selective inhibitor of the protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), demonstrating an IC50 of 0.3 nM. This compound effectively modulates the PERK pathway, which is activated in response to various endoplasmic reticulum stresses associated with numerous disease states. PERK-IN-4 is valuable for research applications focused on cellular stress responses and potential therapeutic strategies in diseases linked to the unfolded protein response. -
PERK Inhibitor
HC-5404-Fu is a potent and orally active inhibitor of the protein kinase PERK, exhibiting an IC50 of 0.001 μM against human PERK. By blocking PERK activation induced by VEGFR-TKIs, HC-5404-Fu disrupts the adaptive stress response that typically enhances tumor survival. This compound enhances anti-angiogenic effects by inhibiting the formation of both newly formed and mature tumor blood vessels, particularly in renal cell carcinoma models. HC-5404-Fu is suitable for research focused on tumor biology and angiogenesis in renal cell carcinoma. -
PERK Inhibitor
PERK-IN-5 is a highly potent inhibitor of PERK (Protein kinase RNA-like endoplasmic reticulum kinase), demonstrating IC50 values of 2 nM and 9 nM for PERK and phosphorylated eIF2α, respectively. This compound is selectively and orally bioavailable, making it an advantageous tool for in vivo studies. PERK-IN-5 has been shown to significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft model, positioning it as a valuable reagent for cancer research focusing on the UPR (unfolded protein response) pathway. -
PERK Inhibitor
(S)-PERK-IN-5 is a selective inhibitor of the protein kinase PERK (PKR-like endoplasmic reticulum kinase), exhibiting an IC50 range of 0.101-0.250 μM. This compound plays a critical role in studies focused on the unfolded protein response and endoplasmic reticulum stress pathways. Its application is pertinent in exploring therapeutic strategies for diseases associated with protein misfolding and metabolic dysregulation. -
PERK Inhibitor
PERK-IN-3 is a highly selective inhibitor of the Protein Kinase R (PKR)-like ER kinase (PERK) with an IC50 value of 7.4 nM. This compound effectively modulates the unfolded protein response, promoting cell survival under ER stress. It is primarily utilized in research investigating the role of PERK in cellular stress pathways, cancer biology, and neurodegenerative diseases. -
PERK Inhibitor
PERK-IN-6 is a selective inhibitor of the Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK), exhibiting an IC50 value of 2.5 nM. This compound inhibits PERK-mediated signaling pathways, making it a valuable tool for investigating the role of ER stress and unfolded protein response in various cellular processes. PERK-IN-6 is suitable for research applications in studying diseases associated with dysregulated PERK activity, including neurodegeneration and cancer. -
MIF Inhibitor
4-IPP (4-Iodo-6-phenylpyrimidine) is a selective suicide substrate and irreversible inhibitor targeting macrophage migration inhibitory factor (MIF). This compound significantly impedes MIF activity, making it a valuable tool for research into inflammatory processes, cancer progression, and immune response modulation. Its ability to inhibit MIF provides insights into the underlying mechanisms of various pathologies, facilitating the development of therapeutic strategies. -
MIF Antagonist
MIF098 is a potent macrophage migration inhibitory factor (MIF) antagonist. It effectively inhibits the proliferation, migration, and fibrosis of pulmonary smooth muscle cells, making it a valuable tool in the study of immunoinflammatory diseases. Research applications include investigating mechanisms of pulmonary disorders and exploring potential therapeutic strategies for related conditions. -
MIF Inhibitor
ISO-92 is a selective inhibitor of migration inhibitory factor (MIF) with an IC50 of 550 nM. This compound effectively reduces inflammatory activity and demonstrates a dose-dependent inhibition of hypoxia-induced proliferation in the CCL-210 cell line. In mouse models of hypoxia, ISO-92 significantly decreases the thickness of the pulmonary vascular wall. Its unique mechanism makes ISO-92 a valuable tool for investigating inflammatory and neurological disorders. -
Antitumor Agent
Mitomycin A is an antitumor agent that exerts its effects primarily through DNA cross-linking, leading to inhibition of cell division. It has been shown to inhibit the spontaneous migration of mouse monocytes and reduce the production of Migration Inhibition Factor (MIF) by human lymphocytes. Mitomycin A is utilized in research focused on tumor biology and the mechanisms of cancer progression, providing insights into potential therapeutic strategies. -
MIF-directed PROTAC
MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. This compound facilitates the targeted degradation of MIF, offering potential utility in cancer research by modulating inflammatory responses associated with tumor progression. Its application may provide insights into therapeutic strategies for malignancies influenced by MIF signaling pathways. -
MIF-2 Inhibitor
4-CPPC is a potent and selective inhibitor of Macrophage Migration Inhibitory Factor 2 (MIF-2), demonstrating a Ki value of 33 µM. This compound exhibits reversible inhibition, showcasing a notable selectivity over MIF-1 with a Ki value of 431 µM. 4-CPPC is valuable for research applications aimed at elucidating the role of MIF-2 in inflammatory responses and other pathological conditions, making it a critical tool for studying MIF-related signaling pathways. -
MIF Inhibitor
RDR 03785 is a covalent inhibitor of Macrophage Migration Inhibitory Factor (MIF), exhibiting an IC50 of 0.36 μM. This compound demonstrates significant biological activity in modulating MIF-related pathways, making it a valuable tool in the study of inflammatory diseases and immune response regulation. Research applications include exploring MIF's role in various pathophysiological processes, as well as potential therapeutic interventions targeting MIF. -
MIF Inhibitor
MKA031 is a non-competitive inhibitor of macrophage migration inhibitory factor (MIF) with an IC50 value of 1.7 μM. This compound disrupts the interaction between MIF and AIF, impedes MIF nuclear translocation, and interferes with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced cell death. MKA031 is particularly useful for research applications focused on chronic hepatitis C virus infection and related cellular pathways. -
MIF2 Tautomerase Inhibitor
R110 is a potent competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase, exhibiting an IC50 of 15 μM. This compound is valuable for research into cancer biology, specifically in mechanisms related to tumor progression and immune modulation. By targeting MIF2, R110 offers potential insights into therapeutic strategies for cancer treatment. -
MIF2 Tautomerase Inhibitor
MIF2-IN-1 is a potent inhibitor of the MIF2 tautomerase, exhibiting an IC50 of 1.0 μM. This compound effectively suppresses the proliferation of non-small cell lung cancer cells by inducing cell cycle arrest through the deactivation of the MAPK signaling pathway. MIF2-IN-1 is a valuable tool for researching cancer biology and therapeutic strategies in oncology. -
MIF Inhibitor
MIF-IN-4 hydrochloride is a potent inhibitor of macrophage migration inhibitory factor (MIF), with an affinity corresponding to a pIC50 of 5.01-6. MIF is a crucial cytokine involved in regulating macrophage migration and immune responses. This compound is valuable for research applications focused on inflammation, immune modulation, and related pathways. -
MIF Inhibitor
MIF-IN-6 is a potent inhibitor of macrophage migration inhibitory factor (MIF), exhibiting an IC50 of 1.4 μM and a Ki value of 0.96 μM. This compound effectively attenuates MIF-induced ERK phosphorylation and inhibits the proliferation of A549 cells, making it valuable for studies related to cancer biology and inflammation. Its mechanism of action positions MIF-IN-6 as a significant tool for exploring MIF-related pathways and potential therapeutic interventions. -
NF-κB Inhibitor, GPx Inhibitor, HIV Replication Inhibitor
α-MSH (11-13) acetate is a selective melanocortin-1 receptor ligand that functions as an inhibitor of NF-κB, GPx activity, and HIV replication. It induces an acute elevation of intracellular calcium levels under certain costimulation or pathway inhibition conditions. This compound effectively suppresses TNF-α-induced NF-κB activation, inhibits colony formation of Staphylococcus aureus and Candida albicans, and demonstrates potential in the study of infections related to these pathogens, as well as in traumatic brain injury, corneal epithelial wounds, and inflammatory bowel disease research. -
PKD inhibitor
CID 2011756 is a protein kinase D (PKD) inhibitor (IC50 values are 0.6, 0.7 and 3.2 μM for PKD2, PKD3 and PKD1 respectively). -
PKD inhibitor
kb NB 142-70 is a selective protein kinase D (PKD) inhibitor (IC50 values are 28.3, 58.7 and 53.2 nM for PKD1, 2 and 3 respectively). -
p53 inhibitor
inhibits p53 binding to mitochondria by reducing its affinity for antiapoptotic proteins Bcl-2 and Bcl-XL. -
p53 inhibitor
Pifithrin-α hydrobromide is a reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription such as cyclin G, p21/waf1, and mdm2 expression.
-
myeloperoxidase inhibitor
PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. -
Caspase-6 inhibitor
Z-VEID-FMK is the specific recognition sequence for caspase-6/Mch2. Z-VEID-FMK is a synthetic peptide that irreversibly inhibits activity of VEID-dependent caspases (e.g., caspase-6). The inhibitor is designed as a methyl ester to facilitate cell permeability. -
RIP1 inhibitor
GSK481 is a novel benzoxazepinone (BOAz) series of RIP1 inhibitors. Receptor Interacting Protein Kinase 1 (RIP1) has been implicated as a key contributor to inflammation through the regulation of programmed necrosis. Inhibition of this kinase has been shown to hinder cell necrotic death, thereby establishing RIP1 as a viable target for the potential treatment of multiple inflammatory diseases. -
Caspase-2 inhibitor
Z-VDVAD-FMK is a cell-permeable, irreversible inhibitor of caspase-2. Caspase inhibitors play an important role in investigating biological processes. - Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.
-
p53R175 activator
NSC 319726 is a potent and selective activator of mutant p53R175 -
antitumor agent
2-Methoxycinnamaldehyde (o-Methoxycinnamaldehyde) is a natural compound of Cinnamomum cassia, with antitumor activity.
